Joseph DeVivo, serving as President and Chief Executive Officer of Butterfly Network, Inc. (NASDAQ:BFLY), executed a sale of 204,725 shares of the company’s Class A Common Stock on July 7, 2026. The aggregate value of this transaction reached approximately $1.61 million. This divestment follows a significant 293% return for the stock over the preceding year, although analytical data indicates the current valuation may exceed fair value estimates. Furthermore, market analysis highlights considerable volatility in the stock’s price movements.
The shares were disposed of at prices fluctuating between $7.735 and $8.11 per share, resulting in a weighted average sale price of $7.873 per share. Crucially, these transactions were conducted under the company’s established sell-to-cover policy. The primary purpose was to satisfy tax withholding obligations associated with the vesting of restricted stock units. The execution of these sales was automatic, meaning they were not at the discretion of Mr. DeVivo.
Post-transaction, Mr. DeVivo’s direct holdings in Class A Common Stock stand at 7,883,844 shares. This current position includes additional shares acquired through the company’s employee stock purchase plan on June 30, 2025, and June 30, 2026. Investors seeking more detailed insights may access additional financial metrics and tips for BFLY.
In other recent corporate developments, Butterfly Network reported its first quarter of 2026 earnings, which surpassed analyst expectations. The company achieved an earnings per share (EPS) of -$0.03, outperforming the forecasted -$0.04. Revenue for the quarter reached $26.5 million, exceeding the anticipated $25.74 million. The company also announced the commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices in Brazil. This move marks Butterfly Network’s entry into the largest medical device market in Latin America, expanding its geographic reach.
Additionally, Butterfly Network disclosed a co-development agreement with Midjourney. Under this agreement, Butterfly’s Ultrasound-on-Chip imaging modules will be incorporated into Midjourney’s full-body imaging scanner. The collaboration is expected to expand in future generations of the scanner, indicating a strategic push into AI-integrated medical imaging. Furthermore, Butterfly Network appointed Caroll H. Neubauer, former CEO of B. Braun USA, to its Board of Directors. Mr. Neubauer will serve on the Compensation and Technology Committees, strengthening the company’s leadership team.
These developments highlight Butterfly Network’s strategic moves in expanding its market presence and strengthening its leadership team. The stock currently trades at 7.34, reflecting a decrease of 0.2400 or 3.17%. After hours trading shows a slight increase to 7.37, up 0.0382 or 0.52%.